ProNAi registers $86.25 million of stock for initial public offering

Jefferies, BofA Merrill Lynch, Wedbush Securities, SunTrust to assist

By Devika Patel

Knoxville, Tenn., June 12 – ProNAi Therapeutics, Inc. will price its initial public sale of common stock with a greenshoe, according to a Form S-1 filed Friday with the Securities and Exchange Commission. The company has registered up to $86.25 million of stock for the deal.

Jefferies LLC and BofA Merrill Lynch are the bookrunners; Wedbush Securities Inc. and SunTrust Robinson Humphrey, Inc. are the co-managers.

Proceeds will be used for clinical trials, manufacturing, non-clinical activities, preclinical activities and product development.

The clinical-stage oncology company is based in Vancouver, B.C. It intends to list its common stock on the Nasdaq under the symbol “DNAI.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.